# Preoperative Hemostatic Management for Refractory Abnormal Uterine Bleeding in Patients With von Willebrand Disease: A Case Report

**Authors:** Rabbania Hiksas, Lisa Novianti, Intan Indah Permatasari, Thalia Amila Elsiyana, Aisyah Retno Puspawardani, Achmad Kemal Harzif

PMC · DOI: 10.1155/crog/5078814 · Case Reports in Obstetrics and Gynecology · 2026-02-25

## TL;DR

A woman with von Willebrand disease and severe uterine bleeding underwent surgery with preoperative hemostatic treatment to prevent excessive bleeding.

## Contribution

This case report highlights the effectiveness of preoperative cryoprecipitate and DDAVP in managing bleeding during surgery in von Willebrand disease.

## Key findings

- Preoperative administration of cryoprecipitate and DDAVP prevented excessive bleeding during surgery.
- Laparoscopy reduced blood loss and surgical hemorrhage risk in this patient.
- A multidisciplinary approach improved hemostatic control and patient care.

## Abstract

von Willebrand disease (VWD) is the most frequent inherited bleeding disorder in women, characterized by quantitative or qualitative deficiency in von Willebrand factor (VWF). This deficiency in functional VWF has a dual effect on hemostasis, resulting in impaired coagulation; thus, it may cause unstoppable abnormal uterine bleeding (AUB).

A 44‐year‐old female complained of AUB for 4 years before admission. She was diagnosed with adenomyosis and had been taking dienogest 1 × 2 mg; however, the bleeding still continued. She was hospitalized due to her heavy bleeding, with her lowest hemoglobin level (7.0 g/dL) and received recurrent blood transfusion. As coagulation disorder was suspected, the laboratory result revealed a low level of Factor VIII (52.0%) and Factor von Willebrand (37.0%), suggestive of Type 2 VWD. She also had generalized anxiety disorder related to her refractory AUB. She then underwent laparoscopy total hysterectomy, right salpingo–oophorectomy, and left salpingectomy for source control. Preoperatively, 2 units of cryoprecipitate and intranasal desmopressin (DDAVP) 300 mcg were given. The medication continued up to 7 days after surgery, with no massive bleeding reported afterwards.

Coagulopathies, including VWD, should always be suspected in patients with refractory AUB. Preoperative medication such as cryoprecipitate products and DDAVP could be given to provide an immediate hemostatic response in preventing excessive bleeding during surgery. Laparoscopy is considered the best surgical approach to ensure less blood loss and lower risk of hemorrhage. A multidisciplinary approach is essential to ensure both effective hemostatic control and comprehensive patient care.

## Linked entities

- **Chemicals:** dienogest (PubChem CID 68861)
- **Diseases:** von Willebrand disease (MONDO:0019565), adenomyosis (MONDO:0010888), generalized anxiety disorder (MONDO:0001942)

## Full-text entities

- **Genes:** VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, TF (transferrin) [NCBI Gene 7018] {aka HEL-S-71p, PRO1557, PRO2086, TFQTL1}, F8 (coagulation factor VIII) [NCBI Gene 2157] {aka AHF, DXS1253E, F8B, F8C, FVIII, HEMA}, GP1BA (glycoprotein Ib platelet subunit alpha) [NCBI Gene 2811] {aka BDPLT1, BDPLT3, BSS, CD42B, CD42b-alpha, DBPLT3}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}
- **Diseases:** iron deficiency (MESH:D000090463), Hemophilia (MESH:D006467), anxiety disorder (MESH:D001008), iron-deficiency anemia (MESH:D018798), inherited (MESH:D030342), dysfunctional uterine bleeding (MESH:D008796), VWD (MESH:D014842), fatigue (MESH:D005221), epistaxis (MESH:D004844), gynecologic disorder (MESH:D005831), Bleeding (MESH:D006470), bruising (MESH:D003288), adenomyosis (MESH:D062788), osteoporosis (MESH:D010024), anxiety (MESH:D001007), blood loss (MESH:D016063), Type 1 VWD (MESH:D056725), Type 2 VWD (MESH:D056728), VWF deficiency (MESH:C531844), inherited bleeding disorder (MESH:D025861), thrombocytopenia (MESH:D013921), postoperative pain (MESH:D010149), Coagulopathies (MESH:D001778), cardiovascular complications (MESH:D002318), quality (MESH:D012893), platelet aggregation (MESH:D001791), presyncope (MESH:D013575), Thrombosis (MESH:D013927), AUB (MESH:D014592), trauma (MESH:D014947), anemia (MESH:D000740), premature ovarian insufficiency (MESH:D016649)
- **Chemicals:** quetiapine (MESH:D000069348), Iron (MESH:D007501), Tranexamic acid (MESH:D014148), ADP (MESH:D000244), ristocetin (MESH:D012310), dienogest (MESH:C023635), alprazolam (MESH:D000525)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12935299/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12935299/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC12935299/full.md

---
Source: https://tomesphere.com/paper/PMC12935299